Background: Immune checkpoint inhibitors are a new promising class of antitumor drugs that
have been associated with a number of immune-related Adverse Events (AEs), including …

Immune checkpoint inhibitors have advanced the treatment paradigm of various cancers,
achieving remarkable survival benefits. However, a myriad of immune-related adverse …

Immune checkpoint inhibitors (ICPIs) have emerged as a frontline treatment for a growing list
of malignancies. Disruption of the negative regulatory immune checkpoints by ICPIs has …

Immune checkpoint inhibitors targeting the cytotoxic T lymphocyte-associated antigen-4 and
programmed cell death-1 receptors have transformed the treatment of melanoma and other …

Simple Summary Granulomatosis is commonly observed in patients receiving immune
checkpoint inhibitors (ICIs) for melanoma and other cancers. Recognizing this reaction early …

In 2020, there were an estimated 19.3 million new cancer cases and close to 10 million
cancer deaths worldwide. Cancer remains one of the leading causes of death. In recent …

Sarcoidosis and sarcoid‐like reactions (SLRs) may develop in association with various
malignancies, as well as in association to certain oncologic drugs, including immune …

Immune checkpoint inhibitors (CPIs) have recently become a cornerstone for the treatment
of different advanced cancers. These drugs have the ability to reactivate the immune system …

Therapy for advanced melanoma has deeply changed in the last decade with the
introduction of checkpoint and BRAF/MEK inhibitors. Granulomatous reactions have been …

Simple Summary Immune checkpoint inhibitors (ICIs) can cause granulomatous and sarcoid-
like lesions (GSLs) in several organs, and limited data existing that adequately inform the …